Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on November 18, 2020, covering events occurring between October 7, 2020, and November 19, 2020. The Company, an emerging growth company incorporated in Delaware, operates in the pharmaceutical sector with a focus on its product Mytesi (crofelemer).
Key Financial Metrics and Capital Structure Changes
The filing details a series of unregistered sales of equity securities involving the exchange of debt and royalty interests for common stock. The filing does not provide specific revenue, profit, cash flow, or margin data for the period.
- Total Shares Issued: 7,443,166 shares of Common Stock were issued between October 7 and November 19, 2020.
- Issuance Price: Shares were issued at the Minimum Price as defined under Nasdaq Listing Rule 5635(d).
- Debt Reduction: $1,200,000 in outstanding secured promissory notes were cancelled in exchange for stock.
- Royalty Interest Cancellation: A royalty interest entitling the holder to $500,000 of future royalties and certain fees was cancelled in exchange for stock.
Material Changes and Transactions
The Company executed three specific exchange agreements resulting in the issuance of more than 5% of its issued and outstanding shares of common stock:
- November 17, 2020: Issued 1,314,974 shares to a holder in exchange for the cancellation of a Royalty Interest valued at $500,000 in future royalties and fees.
- November 18, 2020: Issued 3,157,895 shares to a noteholder in exchange for a $600,000 reduction in the outstanding balance of a secured promissory note.
- November 19, 2020: Issued 2,970,297 shares to a noteholder in exchange for a $600,000 reduction in the outstanding balance of a secured promissory note.
These transactions were conducted in reliance on the exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of unregistered securities sales. The primary contingency noted is the reliance on the Section 3(a)(9) exemption for the validity of these stock issuances.
Key Facts for Investor Verification
- Verify the exact "Minimum Price" per share used for the 7,443,166 shares issued to assess the implied valuation of the debt and royalty interest.
- Confirm the total number of outstanding shares post-transaction to calculate the precise dilution percentage (stated as "more than 5%").
- Review the remaining balance of secured promissory notes and the status of other royalty interests following these cancellations.
- Check the Company's most recent Form 10-Q (filed November 16, 2020) for the baseline share count referenced in this filing.